Many promising cell and gene therapies (CGTs) never make it to patients – not because they fail in the lab, but because their manufacturing processes can’t scale to meet patient demand. Without reliable, automated systems, therapies designed to treat genetic diseases, rare conditions, or cancer often stall before reaching clinical trials. To address this challenge, the Food and Drug Administration (FDA) launched the Advanced Manufacturing Technology Designation program to accelerate the adoption of next-generation platforms that deliver more consistent, and scalable products.
What is the FDA AMT Designation Program?
Unlike traditional regulatory designations linked to a specific therapy or clinical trial, the FDA AMT program recognizes advanced manufacturing innovations. These technologies are designed to improve product quality, reliability, and scalability – all critical for modern CGT approaches.
In advanced therapies, manufacturing performance is as important as clinical data, and developers need platforms that scale from the lab bench to commercial production. The AMT designation derisks and encourages adoption of new technologies that improve manufacturing reliability, product quality, and scalability by providing earlier and more frequent engagement with the FDA – helping therapy developers avoid delays, reduce regulatory uncertainty, and accelerate development.
Why the IRO® platform qualified for Advanced Manufacturing Technology designation
Many legacy systems can’t meet today’s manufacturing demands. Ori’s IRO platform was designed to solve the constraints that slow down CGT manufacturing. It was granted the AMT designation from the FDA based on four core capabilities:
- Closed, automated processing that removes the variability of open, manual systems
- Biology-first engineering that improves transduction efficiency and product consistency
- Modular, scalable hardware that supports the same process from bench-top to GMP
- Flexible, digitally-enabled software that enables monitoring and control over the manufacturing process, across batches and sites
For developers working with therapies that modify a patient’s own genetic material, reproducibility is essential. And for fast-moving or life-threatening diseases, scalable platforms like IRO can reduce time to treatment and support long-term commercial success.
What AMT designation means for cell and gene therapy developers
AMT designation does not directly impact therapeutic approval, but it signals that the manufacturing platform behind it meets FDA expectations for advanced technologies. For companies developing cell and gene therapies, this can help reduce risk, speed up validation, and improve investor confidence.
Adopting an AMT-designated platform like IRO offers developers:
- Earlier and more structured FDA interactions across IND, NDA, and BLA milestones
- Faster feedback loops, reducing late-stage development or manufacturing risks
- Clearer expectations for validation and comparability
- Greater confidence in platform scalability from regulators, payers, and investors
Reducing manufacturing risk is essential in the race to bring new cell and gene therapies to patients – especially in diseases where speed to clinic, and vein-to-vein time, matters.
The role of AMT in the future of CGTs
AMT designation is not a finish line. By using a designated AMT, advanced therapy developers can better infrastructure and reduce friction across development, regulatory submission, and commercialization.
The FDA’s decision to recognize Ori’s IRO platform reinforces a clear trend: the future of cell and gene therapy will be built on novel technologies that delivers consistency, automation, and biology-first performance at scale. For Ori – and for the developers working on the next wave of personalized medicines – it’s a meaningful step toward faster, more reliable patient access.